| Rating | Rating / ranking1 | Status |
|---|---|---|
| Access to Medicine Index (ATMI) | 1st | Among top 4 since 2014 |
| MSCI | AA | ESG Leaders group |
| ISS ESG | B | ESG Leaders group, Prime status |
| Sustainalytics* | Low Risk | Industry ESG Top Rated |
| CDP Climate Change | A | Double A List status (since 2022) |
| CDP Water Security | A |
For more information on our awards and recognition, please click here.
Last update: February 2025
1. Rating/ranking scales: ATMI: Out of the 20 largest research-based pharmaceutical companies as selected by the Access to Medicine Foundation; MSCI: CCC to AAA; ISS ESG: D- to A+; Sustainalytics: Negligible to Severe risk; CDP: D- to A
* Copyright © 2023 Morningstar Sustainalytics. All rights reserved. This publication contains information developed by Sustainalytics (www.sustainalytics.com). Such information and data are proprietary of Sustainalytics and/or its third-party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.